Inactive Instrument

ProLung, Inc.

Equities

LUNG

US74348P2092

Healthcare Facilities & Services

Prolung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

August 25, 2020 at 09:40 pm

ProLung, Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced operating loss was USD 570,790 compared to USD 405,753 a year ago. Net loss was USD 712,876 compared to USD 1.138 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.29 a year ago.

Latest news about ProLung, Inc.

ProLung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23	CI
ProLung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23	CI
ProLung, Inc. Auditor Raises 'Going Concern' Doubt	16/04/23	CI
ProLung, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
ProLung, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
ProLung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	23/05/22	CI
ProLung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/04/22	CI
ProLung, Inc. Auditor Raises 'Going Concern' Doubt	14/04/22	CI
ProLung, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
IONIQ Sciences, Inc. Announces the Appointment of Aaron B. Dorny to Its Board of Directors	07/10/21	CI
Prolung, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	16/08/21	CI
Prolung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	24/05/21	CI
Prolung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	03/05/21	CI
Prolung, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/03/21	CI
ProLung, Inc. announced that it has received $0.182 million in funding	20/12/20	CI
ProLung, Inc. announced a financing transaction	02/12/20	CI
Prolung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	25/08/20	CI
Prolung, Inc. Reports Earnings Results for the Year Ended December 31, 2019	15/07/20	CI
ProLung, Inc. has Changed its Name to IONIQ Sciences Inc	28/05/20	CI
ProLung, Inc. announced that it has received $3 million in funding	21/05/20	CI
Prolung, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	08/05/20	CI
ProLung, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	04/03/20	CI
Robert W. Raybould Step Down from the Board of ProLung, Inc	26/11/19	CI
ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% Sensitivity and 74% Specificity	03/10/19	CI
ProLung, Inc. Announces the Appointment of Leavitt Partners and Rich Mckeown to its Board of Directors	12/08/19	CI

Chart ProLung, Inc.

Duration

Period

More charts

Company Profile

Prolung, Inc. is a development-stage medical technology company specializing in predictive analytic, early stage lung cancer risk testing, which refer to as the ProLung Test. The Company's ProLung Test is developed to immediately assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography (CT) scan. The Company's Lead Product is ProLung Test, which is designed to evaluate the risk of lung cancer in patients with lung nodules in well-controlled clinical trials. The ProLung Test includes components, such as ProLung System and ProLung Test Kit. ProLung System consists of the probe, scanner, tower, monitor, and keyboard which are all medical grade components. This component is available for sale in English, French, German, Spanish, and Italian versions. ProLung Test Kit includes six diaphoretic electrodes, one probe tip and one moistening sponge.

Sector

Healthcare Facilities & Services

More about the company

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
RADNET, INC.	+68.36%	4.32B
DR. LAL PATHLABS LIMITED	+6.69%	2.74B
SYNLAB AG	-2.80%	2.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-50.95%	1.97B
NEOGENOMICS, INC.	-19.10%	1.68B
FLEURY S.A.	-22.51%	1.45B
METROPOLIS HEALTHCARE LIMITED	+16.69%	1.2B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-44.86%	1.12B
VIJAYA DIAGNOSTIC CENTRE LIMITED	+17.43%	975M

Medical & Diagnostic Laboratories